OncoMatch/Clinical Trials/NCT06761027
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
Is NCT06761027 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Anlotinib combined with Sintilimab for locally advanced pancreatic cancer.
Treatment: Anlotinib combined with Sintilimab — This study is a prospective, single-arm, multicenter, phase Ib/II clinical trial that treats previously untreated patients with locally advanced or metastatic pancreatic cancer using mFOLFIRINOX in combination with anlotinib and sintilimab. The purpose of this trial is to evaluate the efficacy and safety of this treatment regimen and to preliminarily explore the correlation between biomarkers and treatment outcomes.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Have already received or are currently receiving additional anti-tumor treatment measures such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, or traditional Chinese medicine treatment
Cannot have received: radiation therapy
Have already received or are currently receiving additional anti-tumor treatment measures such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, or traditional Chinese medicine treatment
Cannot have received: targeted therapy
Have already received or are currently receiving additional anti-tumor treatment measures such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, or traditional Chinese medicine treatment
Cannot have received: immunotherapy
Have already received or are currently receiving additional anti-tumor treatment measures such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, or traditional Chinese medicine treatment
Cannot have received: traditional Chinese medicine
Have already received or are currently receiving additional anti-tumor treatment measures such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, or traditional Chinese medicine treatment
Lab requirements
Kidney function
No severe organic diseases of the kidneys
Liver function
No severe organic diseases of the liver
Cardiac function
No severe organic diseases of the heart
No severe organic diseases of the heart, lungs, brain, liver, kidneys, or other organs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify